ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Autoimmune Diseases
Cognitive Dysfunction
Neoplasm Metastasis

Multiple Sclerosis (MS) trials near Montréal, QC, CAN:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Montreal, Quebec, Canada and 73 other locations

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Montreal, Quebec, Canada and 161 other locations

(IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with m ...

Enrolling
Multiple Sclerosis
Drug: RO7121932 - MAD
Drug: RO7121932 SC - SAD

Phase 1

Roche
Roche

Montreal, Quebec, Canada and 23 other locations

This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Drug: Disease modifying treatment (DMT)
Drug: Ofatumumab

Phase 4

Novartis
Novartis

Granby, Quebec, Canada and 36 other locations

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Remibrutinib
Drug: Teriflunomide

Phase 3

Novartis
Novartis

Montreal, Quebec, Canada and 230 other locations

Locations recently updated

for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS...

Active, not recruiting
Multiple Sclerosis
Drug: RPC-1063

Phase 3

Celgene
Celgene

Montreal, Quebec, Canada and 60 other locations

Status recently updated

) neo-antigen in subjects with relapsing multiple sclerosis (RMS).COVID-19 sub-study:The purpose of this research sub-study is to e...

Enrolling
Active, not recruiting
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Phase 3

Novartis
Novartis

Montreal, Quebec, Canada and 297 other locations

This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple...

Enrolling
Multiple Sclerosis, Primary Progressive
Drug: Ocrelizumab
Drug: Placebo

Phase 3

Roche
Roche

Greenfield Park, Quebec, Canada and 209 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems